Cycloheximide (CHX), an inhibitor of de novo protein synthesis, decreased the half-life of BMAL1 protein expression in MCF-7 and MDA-MB-231 breast cancer cells (Supplementary Figure S3l). Here, BMAL1 is linked to breast carcinoma.